Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Whole Genome Analysis of a Well-Differentiated Liposarcoma Reveals Novel SYT1 and DDR2 Rearrangements

ABSTRACT: We used DNA content-based flow cytometry to distinguish and isolate nuclei from clonal populations in a single liposarcoma prior to array comparative genomic hybridization and whole genome sequencing.

ORGANISM(S): Homo sapiens

PROVIDER: GSE47701 | GEO | 2015/01/01

SECONDARY ACCESSION(S): PRJNA207362

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements.

Project description:Liposarcoma is the most common soft tissue sarcoma, but little is known about the genomic basis of this disease. Given the low cell content of this tumor type, we utilized flow cytometry to isolate the diploid normal and aneuploid tumor populations from a well-differentiated liposarcoma prior to array comparative genomic hybridization and whole genome sequencing. This work revealed massive highly focal amplifications throughout the aneuploid tumor genome including MDM2, a gene that has previously been found to be amplified in well-differentiated liposarcoma. Structural analysis revealed massive rearrangement of chromosome 12 and 11 gene fusions, some of which may be part of double minute chromosomes commonly present in well-differentiated liposarcoma. We identified a hotspot of genomic instability localized to a region of chromosome 12 that includes a highly conserved, putative L1 retrotransposon element, LOC100507498 which resides within a gene cluster (NAV3, SYT1, PAWR) where 6 of the 11 fusion events occurred. Interestingly, a potential gene fusion was also identified in amplified DDR2, which is a potential therapeutic target of kinase inhibitors such as dastinib, that are not routinely used in the treatment of patients with liposarcoma. Furthermore, 7 somatic, damaging single nucleotide variants have also been identified, including D125N in the PTPRQ protein. In conclusion, this work is the first to report the entire genome of a well-differentiated liposarcoma with novel chromosomal rearrangements associated with amplification of therapeutically targetable genes such as MDM2 and DDR2.

| S-EPMC3914808 | biostudies-literature

Genomic characterization of well differentiated/dedifferentiated retroperitoneal liposarcoma

Project description:An integrated profiling approach was performed to define molecular alterations associated to the aggressive behavior of retroperitoneal dedifferentiated liposarcoma. In particular, matched well and dedifferentiated components as well as normal adipose tissues, obtained from the same tumor sites, were comparatively investigated to higlight differences in gene expression.

2021-03-10 | GSE159659 | GEO

Genomic profiling of matched well differentiated and de-differentiated liposarcoma.

Project description:Well-differentiated (WD) and de-differentiated (DD) liposarcoma, subtypes of adipocytic sarcomas, are pathologically and clinically dissimilar, but are poorly distinguishable at the molecular level. These tumors harbor neochromosomes formed from amplifications and rearrangements of chr12q. Nineteen selected patients with matched WD and DD tumors underwent extensive exomic and transcriptomic profiling to distinguish genomic features between the two subtypes. Shared point mutations suggest a common tumor origin and de-differentiated tumors have higher burdens of deletions.

| EGAS00001002807 | EGA

RNA-seq of four tissue samples of dedifferentiated liposarcoma and corresponding matched well-differentiated liposarcoma

Project description:Dedifferentiated liposarcoma (DDL) has the same cellular and molecular genetics features as well-differentiated liposarcoma (WDL), and there is still no ideal biomarker for the prediction of DDL patient prognosis in clinical practice. In order to explore the genes that cause WDL to obtain local invasion and distant metastasis capacities and transform it into DDL, The four DDL tissue specimens in this study were matched with four WDL tissue specimens according to baseline characteristics, such as gender, age, and recurrence, before high-throughput sequencing was conducted. Then total RNAs were subjected to RNA isolation and RNA-seq analyses were generated by deep sequencing using Illumina Hiseq.

2021-09-17 | GSE184199 | GEO

MicroRNA expression profiles do not distinguish between primary and recurrent well-differentiated liposarcoma

Project description:Well-differentiated liposarcoma (WDLPS) recurs in approximately one-third of the patients. The molecular relationship between primary tumor and recurrent tumors is barely studied, but is important to reveal potential drivers of recurrence. Here we investigated the biology of recurrent WDLPS using 27 paired primary and recurrent WDLPS samples. MicroRNA expression profiles were determined using TaqMan® Low Density Array (TLDA)-cards. In the supervised clustering analyses, no clear clustering separating the primary from the recurrent tumors, based on differentially expressed microRNAs was observed. The clustering was also not based on tumor localization, time to recurrence, age or status of the resection margins. Subgroup analysis for tumors localized in the extremity or retroperitoneum also did not yield a clear distinction between primary and recurrent WDLPS. In conclusion, microRNA expression profiles do not distinguish between primary and recurrent WDLPS and no putative common drivers for recurrence could be identified.

2019-09-20 | GSE137722 | GEO

MicroRNA expression profiles do not distinguish between primary and recurrent well-differentiated liposarcoma

Project description:MicroRNA expression profiles do not distinguish between primary and recurrent well-differentiated liposarcoma

| PRJNA566391 | ENA

Genomic characterization of well differentiated/dedifferentiated retroperitoneal liposarcoma

Project description:Genomic characterization of well differentiated/dedifferentiated retroperitoneal liposarcoma

| PRJNA670101 | ENA

RNA-seq of four tissue samples of dedifferentiated liposarcoma and corresponding matched well-differentiated liposarcoma

Project description:RNA-seq of four tissue samples of dedifferentiated liposarcoma and corresponding matched well-differentiated liposarcoma

| PRJNA763563 | ENA

Aberrant AKT activation drives well-differentiated liposarcoma.

Project description:Well-differentiated liposarcoma (WDLPS), one of the most common human sarcomas, is poorly responsive to radiation and chemotherapy, and the lack of animal models suitable for experimental analysis has seriously impeded functional investigation of its pathobiology and development of effective targeted therapies. Here, we show that zebrafish expressing constitutively active Akt2 in mesenchymal progenitors develop WDLPS that closely resembles the human disease. Tumor incidence rates were 8% in p53 wild-type zebrafish, 6% in p53 heterozygotes, and 29% in p53-homozygous mutant zebrafish (P = 0.013), indicating that aberrant Akt activation collaborates with p53 mutation in WDLPS pathogenesis. Analysis of primary clinical specimens of WDLPS, and of the closely related dedifferentiated liposarcoma (DDLPS) subtype, revealed immunohistochemical evidence of AKT activation in 27% of cases. Western blot analysis of a panel of cell lines derived from patients with WDLPS or DDLPS revealed robust AKT phosphorylation in all cell lines examined, even when these cells were cultured in serum-free media. Moreover, BEZ235, a small molecule inhibitor of PI3K and mammalian target of rapamycin that effectively inhibits AKT activation in these cells, impaired viability at nanomolar concentrations. Our findings are unique in providing an animal model to decipher the molecular pathogenesis of WDLPS, and implicate AKT as a previously unexplored therapeutic target in this chemoresistant sarcoma.

| S-EPMC3182699 | biostudies-literature

Whole genome sequencing of human well differentiated retroperitoneal liposarcoma samples

Project description:Whole genome sequencing of human well differentiated retroperitoneal liposarcoma samples

| PRJEB16017 | ENA